[ORGANIZATION]
JAMA Dermatology
Featured in 5 tracked stories · first seen
Situations
Upadacitinib clinical trial results
2 clusters · 8 sources · last updated
Latest: Upadacitinib shows efficacy in severe alopecia areata phase 3 trials
Clinical trials have demonstrated the efficacy of the oral Janus kinase (JAK) inhibitor upadacitinib in treating various skin and hair conditions. Research published in The Lancet regarding vitiligo indicates that a onc
Health impacts and risks of UV exposure
5 clusters · 20 sources · last updated
Latest: Severe sunburns increase skin cancer risk, study finds
Discussions regarding UV exposure focus on the tension between health benefits, such as vitamin D synthesis and mood regulation, and the risks of skin cancer and premature aging. Initial reports from Mexican Sun addresse
Upadacitinib clinical trials for alopecia areata
3 clusters · 12 sources · last updated
Latest: Upadacitinib shows significant hair regrowth in severe alopecia areata trials
Two phase 3 clinical trials, UP-AA1 and UP-AA2, have demonstrated that the JAK inhibitor upadacitinib (brand name Rinvoq) shows significant promise in treating severe alopecia areata. The studies, published in JAMA Derma
Also covered in
-
Severe sunburns linked to increased skin cancer risk
[HEALTH] · 6 sources ·